高级检索

磁共振PI-RADS评分联合18F-PSMA PET/CT在前列腺癌的诊断效能研究

Effectiveness of PI-RADS of MRI combined with 18F-PSMA PET/CT in diagnosis of prostate cancer

    摘要
  • 摘要:
    背景 前列腺癌已居老年男性恶性肿瘤发病率第二位，其早期筛查有重要临床意义。
    目的 探索前列腺影像报告和数据系统(PI-RADS)评分联合18氟标记前列腺特异性膜抗原PET/CT (18F-PSMA PET/CT)评分对前列腺癌的诊断价值。
    方法  回顾性分析2019 年1月— 2022 年11月在解放军总医院行前列腺穿刺活检或手术的124例患者的前列腺磁共振检查(MRI)及18F-PSMA PET/CT的影像资料，2名影像医师和2名核医学科医师分别对MRI图像和PET/CT图像进行PI-RADS评分和分子成像前列腺特异性膜抗原(miPSMA)评分。以病理结果为金标准，分别以PI-RADS≥3分，miPSMA≥2分，PI-RADS≥3分联合miPSMA≥2作为前列腺癌的不同诊断模型，评估各模型的诊断效能。
    结果 124例受试者平均年龄77.74 ± 10.30岁，100例被确诊为前列腺癌。以PI-RADS≥3分、miPSMA≥2分以及PI-RADS≥3分联合miPSMA≥2为标准诊断前列腺癌的灵敏度分别为99.0%，96.0%和95.0%；特异度分别为33.3%，83.3%和83.3%；准确度分别为86.3%，93.5%和92.7%；曲线下面积(AUC)分别为0.662(0.523 ~ 0.800)、0.897(0.806 ~ 0.987)和0.892(0.801 ~ 0.983)。
    结论 前列腺PI-RADS评分≥3分联合miPSMA≥2有着较高的诊断效能，可作为前列腺癌的精准诊断方案应用于临床。

     

    Abstract:
    Background Prostate cancer has become the second most common malignant tumor in older men, and its early screening is particularly important.
    Objective  To explore the value of prostate imaging reporting and data system (PI-RADS) score based on magnetic resonance imaging (MRI) combined with molecular prostate specific membrane antigen(miPSMA) score based on 18-fluoro-labeled prostate specific membrane antigen PET/CT imaging (18F-PSMA PET/CT) in the diagnosis of prostate cancer.
    Methods  The MRI of the prostate and 18F-PSMA PET/CT in 124 cases who underwent prostate puncture biopsy or surgery in Chinese PLA General Hospital from January 2019 to November 2022 were retrospective analyzed by two radiologists and two nuclear medicine physicians independently for PI-RADS score and miPSMA score. According to the pathological results, the efficacy of three different diagnostic models including PI-RADS ≥3, miPSMA ≥2, and PI-RADS ≥3 combined with miPSMA ≥2 were evaluated, respectively.
    Results  The mean age of the 124 subjects was 77.74 ± 10.30 years and 100 subjects were diagnosed with prostate cancer. The sensitivity of diagnosing prostate cancer using PI-RADS ≥3, miPSMA ≥2, and PI-RADS ≥3 combined with miPSMA ≥2 as criteria was 99.0%, 96.0%, and 95.0%, the specificity was 33. 3%, 83.3% and 83.3%, the accuracy was 86.3%, 93.5% and 92.7%, and area under the curve (AUC) was 0.662 (0.523-0.800), 0.897 (0.806-0.987) and 0.892 (0.801-0.983), respectively.
    Conclusion  PI-RADS≥3 combined with miPSMA ≥2 has a high diagnostic efficacy and can be used as imaging diagnostic model for prostate cancer in clinical practice.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回
下载中心
    友情链接